Zogenix

Latest articles

8d
FOX Business
These 6 Stocks Make Up 58% of the First-Ever Marijuana ETFs Holdingsreduction in seizure frequency relative to the placebo. The pressing issue for
FOX Business / Posted 8 days ago
reduction in seizure frequency relative to the placebo. The pressing issue for GW Pharmaceuticals is that a rival, Zogenix, recently reported promising data for its low-dose fenfluramine hydrochloride as a treatment for Dravet syndrome.... Read more
8d
FOX Business
These 6 Stocks Make Up 58% of the First-Ever Marijuana ETFs Holdingsreduction in seizure frequency relative to the placebo. The pressing issue for
FOX Business / Posted 8 days ago
reduction in seizure frequency relative to the placebo. The pressing issue for GW Pharmaceuticals is that a rival, Zogenix, recently reported promising data for its low-dose fenfluramine hydrochloride as a treatment for Dravet syndrome.... Read more
15d
FOX Business
This Potential Billion-Dollar Marijuana-Based Drug Suddenly Finds Itself in Deep Trouble$1 billion in annual sales at its peak was not out of the question. Well, folk
FOX Business / Posted 15 days ago
$1 billion in annual sales at its peak was not out of the question. Well, folks, that cakewalk just became quicksand.Enter Zogenix, stage right Last week, small-cap biotech Zogenix(NASDAQ: ZGNX) shocked Wall Street and investors by unveiling phase... Read more
15d
FOX Business
This Potential Billion-Dollar Marijuana-Based Drug Suddenly Finds Itself in Deep Troubleat its peak was not out of the question. Continue Reading Below Well, folks,
FOX Business / Posted 15 days ago
at its peak was not out of the question. Continue Reading Below Well, folks, that cakewalk just became quicksand.Enter Zogenix, stage right Last week, small-cap biotech Zogenix(NASDAQ: ZGNX) shocked Wall Street and investors by unveiling phase... Read more
19d
FOX Business
Zogenix Soars 10% Today Despite Diluting Investorsfor money to fuel R&D (research and development) and pre-commercialization effo
FOX Business / Posted 19 days ago
for money to fuel R&D (research and development) and pre-commercialization efforts for its Dravet syndrome drug, shares in Zogenix(NASDAQ: ZGNX) are rallying 10% at 2 p.m. EDT today.So what Dravet syndrome patients receiving ZX008 saw the average... Read more
19d
FOX Business
Zogenix Soars 10% Today Despite Diluting Investorsfor money to fuel R&D (research and development) and pre-commercialization effo
FOX Business / Posted 19 days ago
for money to fuel R&D (research and development) and pre-commercialization efforts for its Dravet syndrome drug, shares in Zogenix(NASDAQ: ZGNX) are rallying 10% at 2 p.m. EDT today.So what Dravet syndrome patients receiving ZX008 saw the average... Read more
21d
FOX Business
3 Biotech Stocks That Soared This Week: Are They Buys?biotechs over the last few days. Madrigal Pharmaceuticals(NASDAQ: MDGL), Spect
FOX Business / Posted 21 days ago
biotechs over the last few days. Madrigal Pharmaceuticals(NASDAQ: MDGL), Spectrum Pharmaceuticals(NASDAQ: SPPI), and Zogenix(NASDAQ: ZGNX) reaped the rewards from recent announcements of clinical results for their respective products, with... Read more
3 related articles
21d
FOX Business
3 Biotech Stocks That Soared This Week: Are They Buys?last few days. Continue Reading Below Madrigal Pharmaceuticals(NASDAQ: MDGL),
FOX Business / Posted 21 days ago
last few days. Continue Reading Below Madrigal Pharmaceuticals(NASDAQ: MDGL), Spectrum Pharmaceuticals(NASDAQ: SPPI), and Zogenix(NASDAQ: ZGNX) reaped the rewards from recent announcements of clinical results for their respective products, with... Read more
3 related articles
21d
FOX Business
A Tiny Biotech Just Dealt a Big Blow to Marijuana's Use in EpilepsyOn Friday, clinical-stage drug developer Zogenix(NASDAQ: ZGNX) reported results
FOX Business / Posted 21 days ago
On Friday, clinical-stage drug developer Zogenix(NASDAQ: ZGNX) reported results from the first of two trials evaluating the use of low-dose fenfluramine (ZX008) in patients with a rare form of epilepsy called Dravet syndrome. The results demonstrated... Read more
21d
FOX Business
A Tiny Biotech Just Dealt a Big Blow to Marijuana's Use in EpilepsyOn Friday, clinical-stage drug developer Zogenix(NASDAQ: ZGNX) reported results
FOX Business / Posted 21 days ago
On Friday, clinical-stage drug developer Zogenix(NASDAQ: ZGNX) reported results from the first of two trials evaluating the use of low-dose fenfluramine (ZX008) in patients with a rare form of epilepsy called Dravet syndrome. The results demonstrated... Read more
22d
FOX Business
Why GW Pharmaceuticals, Louisiana-Pacific, and IAMGOLD Slumped Todayas Dravet syndrome, and investors have been optimistic about GW's prospects in
FOX Business / Posted 22 days ago
as Dravet syndrome, and investors have been optimistic about GW's prospects in the space. However, a small company called Zogenix said today that it had seen positive study results for its own Dravet syndrome treatment, including reduced seizure... Read more
3 related articles
22d
FOX Business
Why GW Pharmaceuticals, Louisiana-Pacific, and IAMGOLD Slumped Todayas Dravet syndrome, and investors have been optimistic about GW's prospects in
FOX Business / Posted 22 days ago
as Dravet syndrome, and investors have been optimistic about GW's prospects in the space. However, a small company called Zogenix said today that it had seen positive study results for its own Dravet syndrome treatment, including reduced seizure... Read more
3 related articles
22d
FOX Business
Why Zogenix Inc. Stock More Than Doubled Todayas a result of the news about ZX008.Now what While the market is clearly celeb
FOX Business / Posted 22 days ago
as a result of the news about ZX008.Now what While the market is clearly celebrating this positive clinical trial data, Zogenix still plans to wait for the drug's second trial to wrap up before filing for its approval with American and European... Read more
3 related articles
22d
FOX Business
Why Zogenix Inc. Stock More Than Doubled Todayabout ZX008.Now what Continue Reading Below While the market is clearly celeb
FOX Business / Posted 22 days ago
about ZX008.Now what Continue Reading Below While the market is clearly celebrating this positive clinical trial data, Zogenix still plans to wait for the drug's second trial to wrap up before filing for its approval with American and European... Read more
3 related articles
22d
Market Watch
UPDATE: Zogenix stock rockets 195% premarket on news of positive epilepsy drug trialZogenix Inc. shares ZGNX, -8.36% rocketed almost 200% Friday, after the company
Market Watch / Posted 22 days ago
Zogenix Inc. shares ZGNX, -8.36% rocketed almost 200% Friday, after the company said a late-stage trial of a treatment for a rare type of epilepsy called Dravet syndrome met its main goal. The Phase 3 trial of the drug, ZX008, low-dose fenfluramine... Read more

In this news